Actuate Therapeutics is focused on developing innovative cancer therapies, particularly through its lead drug, elraglusib, which is a novel GSK-3 inhibitor. This drug targets multiple molecular pathways that are crucial for tumor growth and resistance to conventional treatments like chemotherapy. Elraglusib not only inhibits the GSK-3β enzyme, which is known to promote cancer cell proliferation and survival, but it also plays a role in enhancing anti-tumor immunity by modulating immune checkpoints and regulating immune cell functions. This multi-faceted approach positions elraglusib as a promising candidate for treating various hard-to-treat cancers, potentially leading to improved patient outcomes with minimal adverse effects.

The company is actively conducting clinical trials for elraglusib across several cancer types, including pancreatic cancer, melanoma, and Ewing sarcoma. These cancers are characterized by high mortality rates and limited treatment options, underscoring the urgent need for effective therapies. Elraglusib has shown encouraging preclinical and clinical evidence of antitumor activity, with the potential to improve responses in tumors that have previously been resistant to treatment. Additionally, the development of an oral formulation of elraglusib aims to enhance patient compliance and accessibility, making it a significant advancement in cancer therapy.

United States

Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the treatment of cancer and inflammatory diseases leading to fibrosis.

Cancer

Inflammatory disorders

Actuate Therapeutics

Advanced Salivary Gland Carcinoma

Elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.

Actuate Therapeutics

Company Details